Skip to main content
. 2022 Nov 5;6:83. doi: 10.1038/s41698-022-00327-y

Fig. 3. Potential therapeutic targets in GBC.

Fig. 3

A Total tumor mutational burden (TMB), B Microsatellite instability (MSI), C Integrative overview of immunotherapy biomarkers (TMB, MSI), clinically relevant mutations (class 4 and 5), gene amplifications, transcripts and immunohistochemistry results. NA not applicable.